Case Reports
Vol. 2 No. 1 (2023)
A case of acquired factor XIII deficiency secondary to plasmablastic lymphoma
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 25 October 2022
Accepted: 20 February 2023
Accepted: 20 February 2023
937
Views
416
Downloads
Authors
Acquired factor XIII (FXIII) deficiency is an extremely rare and potentially fatal bleeding disorder. Immune-mediated FXIII deficiency is due to the development of anti-FXIII autoantibodies which may develop with concomitant conditions that cause immune dysregulation such as malignancies or autoimmune disorders. Clinical presentation includes delayed post-operative bleeding or spontaneous soft tissue hematomas and/or cerebral bleeding. Since screening coagulation laboratory tests (prothrombin time, activated partial thromboplastin time, and fibrinogen) are typically normal, acquired FXIII deficiency is likely to be overlooked and underdiagnosed. The management of immune-mediated FXIII deficiency is based on hemostatic therapy, autoantibody removal and eradication of the underlying etiology; however, no treatment guidelines are still available. Here we report a case of acquired FXIII deficiency associated with plasmablastic lymphoma, in order to raise awareness of this rare bleeding disorder and consent prompt life-saving management.
Downloads
Download data is not yet available.
Citations
Yan MTS, Rydz N, Goodyear D, Sholzberg M. Acquired factor XIII deficiency: A review. Transfus Apher Sci 2018;57:724-30. DOI: https://doi.org/10.1016/j.transci.2018.10.013
Chou SC, Lin CY, Yen CT, et al. Acquired FXIII inhibitor: Patient characteristics and treatment outcome, a case series in Taiwan. J Formos Med Assoc 2021;120:411-4. DOI: https://doi.org/10.1016/j.jfma.2020.05.032
Dorgalaleh A, Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev 2016;30:461-75. DOI: https://doi.org/10.1016/j.blre.2016.06.002
Muszbek L, Katona É. Diagnosis and Management of Congenital and Acquired FXIII Deficiencies. Semin Thromb Hemost 2016;42:429-39. DOI: https://doi.org/10.1055/s-0036-1572326
Ichinose A, Kohler HP, Philippou H. Factor XIII and Fibrinogen SSC Subcommittee of the ISTH. Recommendation for ISTH/SSC Criterion 2015 for autoimmune acquired factor XIII/13 deficiency. Thromb Haemost 2016;116:772-4. DOI: https://doi.org/10.1160/TH16-05-0362
Durda MA, Wolberg AS, Kerlin BA. State of the art in factor XIII laboratory assessment. Transfus Apher Sci 2018;57:700-4. DOI: https://doi.org/10.1016/j.transci.2018.07.006
Ichinose A. Japanese Collaborative Research Group on AH13. Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13 antibodies: A summary of 93 patients. Blood Rev 2017;31:37-45. DOI: https://doi.org/10.1016/j.blre.2016.08.002
Suarez-Londono JA, Rohatgi A, Antoine-Pepeljugoski C, Braunstein MJ. Aggressive presentation of plasmablastic myeloma. BMJ Case Rep 2020;13:e234436. DOI: https://doi.org/10.1136/bcr-2020-234436
Ferretti A, Baldacci E, Fazio F, et al. Acquired FXIII deficiency and AL amyloidosis: A case of a rare association. Transfus Apher Sci 2020;59:102903. DOI: https://doi.org/10.1016/j.transci.2020.102903
Kariyawasan CC, Hughes DA, Jayatillake MM, Mehta AB. Multiple myeloma: causes and consequences of delay in diagnosis. QJM 2007;100:635-40. DOI: https://doi.org/10.1093/qjmed/hcm077
How to Cite
1.
Sammartano V, Santoni A, Zappone E, Calzoni P, Fineschi D, Franceschini E, et al. A case of acquired factor XIII deficiency secondary to plasmablastic lymphoma. Bleeding Thromb Vascul Biol [Internet]. 2023 Mar. 9 [cited 2026 Jan. 22];2(1). Available from: https://www.btvb.org/btvb/article/view/53
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Similar Articles
- Silvia Linari, Renato Marino, Marzia Leotta, Antonio Coppola, Patrizia Di Gregorio, Augusto Bramante Federici, Flora Peyvandi, Cristina Santoro, Ezio Zanon, Rita Carlotta Santoro, The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- Renato Marino, Silvia Linari, Marzia Leotta, Antonio Coppola, Chiara Biasoli, Maria Elisa Mancuso, Flora Peyvandi, Cristina Santoro, Ezio Zanon, Rita Carlotta Santoro, Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- PO75 | Prophylaxis with RFXIII: a clinical case in a pediatric patient with congenital FXIII deficiency and delayed diagnosis , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Alice Lipari, Esmeralda Capristo, Antonietta Ferretti, Erica De Candia, Anticoagulation in obese patients: challenges and strategies , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- Roger Lijnen, Désiré Collen, The key to fibrinolysis and thrombolysis , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- PO40 | Management of paediatric patients affected by mild factor VII deficiency undergoing surgery , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO27 | B-cell lymphoproliferative disorder and acquired coagulopathy: an insidious link , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO49 | Use of emicizumab in two patients with acquired hemophilia A: a new therapeutic approach , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO44 | Emicizumab in acquired haemophilia A , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO39 | Bleeding events in Von Willebrand disease type 1 yearly treatable with desmopressin , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
1-10 of 185
Next
You may also start an advanced similarity search for this article.
Most read articles by the same author(s)
- Luca Puccetti, Vincenzo Sammartano, Federico Caroni, Margherita Malchiodi, Paola Calzoni, Eleonora Franceschini, Lucrezia Galasso, Monica Bocchia, Safety of COVID-19 mRNA vaccination in patients with history of acquired hemophilia A: a case series , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
